{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:04:35Z","timestamp":1790057075678,"version":"4.0.1"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) across multiple organs. High-throughput omics approaches may help characterize susceptibility, molecular mechanisms, diagnostic features, and monitoring markers related to irAEs; however, evidence remains dispersed across platforms, clinical applications, and toxicity phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To map original human evidence in which high-throughput omics approaches were directly linked to irAE susceptibility, occurrence, severity, diagnosis, longitudinal monitoring, clinical course, recovery, response to irAE-directed treatment, or mechanistic characterization. Methods: This scoping review and evidence map followed a registered protocol and was informed by PRISMA-ScR and JBI guidance. PubMed\/MEDLINE, Scopus, Web of Science Core Collection, and Embase were searched from January 1, 2014, with the final database search completed on July 9, 2026. Eligible studies involved ICI-exposed patients or human biospecimens, implemented high-throughput genomics\/statistical genetics, transcriptomics, proteomics, metabolomics\/lipidomics, microbiome\/metagenomics, single-cell or spatial omics, immune-repertoire sequencing, or integrated multi-omics approaches, and directly evaluated an irAE outcome. Genome-wide statistical-genetic studies were retained as a conditional evidence category. Targeted single-marker studies, routine laboratory biomarkers, efficacy-only omics analyses, non-ICI populations, non-original reports, case reports, and preclinical-only omics studies were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The searches identified 4,669 records. After removal of 1,151 duplicates, 3,518 unique records were screened and 433 reports were sought for retrieval. Thirty-two reports could not be retrieved for full-text assessment. Of 401 reports assessed in full text, 315 were excluded and 86 studies were included. Omics domains were non-mutually exclusive: transcriptomics was used in 50 studies, single-cell\/spatial omics in 31, proteomics in 20, microbiome\/metagenomics in 20, immune-repertoire sequencing in 16, genomics\/statistical genetics in 14, and metabolomics\/lipidomics in 6. Forty-seven studies contributed to two or more omics domains in the platform audit; after accounting for overlapping analytical modalities, 35 studies met the predefined criteria for true multi-omics integration involving independent molecular layers. Forty-five studies addressed mixed or general irAEs; among organ-specific studies, myocarditis\/cardiovascular toxicity (n=10), pneumonitis\/lung toxicity (n=9), and gastrointestinal\/colitis toxicity (n=8) were most frequent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The high-throughput omics literature directly evaluating irAEs is substantially smaller than the broader biomarker literature and is dominated by transcriptomic and single-cell approaches. Most evidence remains exploratory, with limited independent assessment of predefined models or signatures, incomplete coverage of endocrine, renal, neurologic, hematologic, pancreatic, and musculoskeletal toxicities, and substantial gaps between molecular discovery and clinical implementation. Prospective multicenter cohorts, standardized irAE phenotyping, longitudinal sampling, and independent validation are required to support clinical implementation. Future studies integrating multiple molecular layers with advanced computational approaches may improve biomarker discovery and individualized risk stratification but require transparent development and rigorous validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/osf.io\/g79cv<\/jats:ext-link>\n                      , identifier g79cv.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1945286","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:29Z","timestamp":1790055569000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Omics-based biomarkers of immune-related organ toxicities associated with immune checkpoint inhibitors: a scoping review and evidence map"],"prefix":"10.3389","volume":"17","author":[{"given":"Jianfei","family":"Lu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Macau","place":["Macao, Macao SAR, China"]},{"name":"Tianjin Key Laboratory of Clinical Multi-Omics","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2018894","article-title":"Biomarkers and risk factors for the early prediction of immune-related adverse events: a review","volume":"18","author":"Zhang","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.89376","article-title":"Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers","volume":"20","author":"Miao","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.908752","article-title":"Predictive biomarkers of severe immune-related adverse events with immune checkpoint inhibitors: prevention, underlying causes, intensity, and consequences","volume":"9","author":"Carde\u00f1a-Guti\u00e9rrez","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000957","article-title":"Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events","volume":"35","author":"Desilets","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-025-01026-w","article-title":"Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention","volume":"22","author":"Gao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7326\/m18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B9","doi-asserted-by":"crossref","unstructured":"Aromataris\n              E\n            \n            \n              Lockwood\n              C\n            \n            \n              Porritt\n              K\n            \n            \n              Pilla\n              B\n            \n            \n              Jordan\n              Z\n            \n          \n          Adelaide, SA\n          JBI\n          JBI Manual for Evidence Synthesis\n          \n          2024","DOI":"10.46658\/JBIMES-24-01"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.11124\/jbies-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2025.101488","article-title":"Plasma proteome-driven liquid biopsy for individualized monitoring and risk stratification of immune-related adverse events in checkpoint immunotherapy","volume":"25","author":"Yan","year":"2026","journal-title":"Mol Cell Proteomics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41698-024-00715-6","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis","volume":"8","author":"Zhang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02895-x","article-title":"Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis","volume":"30","author":"Thomas","year":"2024","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202311-2136OC","article-title":"Autoimmunity against surfactant protein B is associated with pneumonitis during checkpoint blockade","volume":"210","author":"Wyss","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15077","article-title":"Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles","volume":"14","author":"Torasawa","year":"2023","journal-title":"Thorac Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13073-021-00974-z","article-title":"Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma","volume":"13","author":"Usyk","year":"2021","journal-title":"Genome Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s12890-025-04005-0","article-title":"Checkpoint inhibitor\u2013associated pneumonitis in non-small cell lung cancer: a cohort study with transcriptomic analysis of inflammatory mechanisms","volume":"25","author":"Zhao","year":"2025","journal-title":"BMC Pulm Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012350","article-title":"Clonally expanded effector CD4+ cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy","volume":"13","author":"Giguelay","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111412","article-title":"Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor","volume":"127","author":"Yu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70265","article-title":"Transcriptomic determinants of circulating immunity predict immune-related adverse events (irAEs) in cancer patients receiving PD-1\/PD-L1 blockade","volume":"17","author":"You","year":"2026","journal-title":"Thorac Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00439","article-title":"Association of baseline tumor-specific neoantigens and CD8+ T-cell infiltration with immune-related adverse events secondary to immune checkpoint inhibitors","volume":"8","author":"Kerepesi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109946","article-title":"Proteomic and metabolomic profiling of plasma predicts immune-related adverse events in older patients with advanced non-small cell lung cancer","volume":"27","author":"Gao","year":"2024","journal-title":"iScience"},{"key":"B24","doi-asserted-by":"publisher","first-page":"18800","DOI":"10.1038\/s41598-026-46960-6","article-title":"Blood parameters and whole-blood transcriptomics associated with immune-related adverse events in metastatic renal cell carcinoma during nivolumab plus ipilimumab","volume":"16","author":"Kinase","year":"2026","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014178","article-title":"Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries","volume":"14","author":"Astbury","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1758205","article-title":"Single-cell profiling of PBMCS reveals an immune signature of irAEs in anti-PD-1-treated acral melanoma patients","volume":"17","author":"Bao","year":"2026","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70310","article-title":"Analysis of peripheral T cell profiling and plasma proteomics in advanced NSCLC patients treated with atezolizumab","volume":"117","author":"Mouri","year":"2026","journal-title":"Cancer Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2026.178569","article-title":"Unraveling sex-related cardiovascular toxicity of immune checkpoint inhibitors by pharmacovigilance and single-cell transcriptomic analysis","volume":"1015","author":"Sang","year":"2026","journal-title":"Eur J Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012270","article-title":"Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis","volume":"13","author":"Deng","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071717","article-title":"Circulating plasma proteins as biomarkers for immunotherapy toxicity: insights from proteome-wide Mendelian randomization and bioinformatics analysis","volume":"13","author":"Tang","year":"2025","journal-title":"Biomedicines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s43556-025-00291-6","article-title":"Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1\/PD-L1 blockades in NSCLC: a prospective exploratory study","volume":"6","author":"Gao","year":"2025","journal-title":"Mol BioMed"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011636","article-title":"Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC","volume":"13","author":"Kim","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s00262-025-04033-z","article-title":"Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury","volume":"74","author":"Ji","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00011-024-01979-1","article-title":"Mediation of macrophage M1 polarization dynamics change by ubiquitin-autophagy-pathway regulated NLRP3 inflammasomes in PD-1 inhibitor-related myocardial inflammatory injury","volume":"74","author":"Chen","year":"2025","journal-title":"Inflammation Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010680","article-title":"Urine proteomics defines an immune checkpoint-associated nephritis signature","volume":"13","author":"Long","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00810-4","article-title":"A targetable type III immune response with increase of IL-17A expressing CD4(+) T cells is associated with immunotherapy-induced toxicity in melanoma","volume":"5","author":"Dimitriou","year":"2024","journal-title":"Nat Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0900","article-title":"Tyrosine protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma","volume":"30","author":"Monson","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009399","article-title":"Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1\/PD-L1 inhibitors","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1229823","article-title":"A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome","volume":"14","author":"Marsiglio","year":"2023","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4006","article-title":"Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis","volume":"15","author":"Halsey","year":"2023","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad056","article-title":"Peripheral immune mapping and multi-omics analysis in Pd-1 inhibitor-induced myocarditis","volume":"114","author":"Gao","year":"2023","journal-title":"J Leukoc Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1112222","article-title":"Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100868","article-title":"Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors","volume":"4","author":"Bukhari","year":"2023","journal-title":"Cell Rep Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032221","article-title":"Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194576","article-title":"Clinical presentation and prognostic features in patients with immunotherapy-induced vitiligo-like depigmentation: a monocentric prospective observational study","volume":"14","author":"Hermann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01965-2","article-title":"Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome","volume":"28","author":"Simpson","year":"2022","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.03.039","article-title":"Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma","volume":"77","author":"Chuah","year":"2022","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13062","article-title":"Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis","volume":"16","author":"Sakurai","year":"2022","journal-title":"Mol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory t-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa115","article-title":"Predicting toxicity and response to pembrolizumab through germline genomic HLA class 1 analysis","volume":"5","author":"Iafolla","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0196","article-title":"The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer","volume":"8","author":"Hakozaki","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf376","article-title":"Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease","volume":"30","author":"Barberio","year":"2025","journal-title":"Oncologist"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00572-5","article-title":"Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer","volume":"4","author":"Sung","year":"2023","journal-title":"Nat Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02805-4","article-title":"Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis","volume":"42","author":"Cui","year":"2023","journal-title":"Oncogene"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70204","article-title":"GWAS identifies SNPs associated with severe adverse events and efficacy in advanced renal cell carcinoma treated with nivolumab","volume":"116","author":"Tanegashima","year":"2025","journal-title":"Cancer Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07426-3","article-title":"Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer","volume":"208","author":"Foldi","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005323","article-title":"Single-cell transcriptomics identifies pathogenic t-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","volume":"10","author":"Franken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s12967-025-06551-x","article-title":"Single-cell transcriptomic analysis deciphers the inflammatory microenvironment characterized by CXCL9+ fibroblasts and ACKR1+ endothelial cells in immune-related myocarditis","volume":"23","author":"Sun","year":"2025","journal-title":"J Transl Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.124.325652","article-title":"Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis","volume":"136","author":"Huang","year":"2025","journal-title":"Circ Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiaf181","article-title":"Single-cell transcriptomic analysis reveals RNA-binding protein dysregulation in immune checkpoint inhibitor-induced colitis","volume":"118","author":"Ran","year":"2026","journal-title":"J Leukoc Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s40168-026-02419-4","article-title":"Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer","volume":"14","author":"Diop","year":"2026","journal-title":"Microbiome"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218168","article-title":"A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients receiving PD-1\/PD-L1 inhibitors","volume":"639","author":"She","year":"2026","journal-title":"Cancer Lett"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047916","article-title":"Explore the potential mediating role of plasma metabolites and cytokines in the causal relationship between gut microbiota and the severity of immune-related adverse events: a Mendelian randomization study","volume":"105","author":"Liu","year":"2026","journal-title":"Med (Baltimore)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"11565","DOI":"10.1038\/s41467-025-67689-2","article-title":"Distinct immune cell dynamics associated with immune-related adverse events during combined chemoradiation and immune checkpoint inhibitor therapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012012","article-title":"Genetic haplotypes in VWA8, OSBPL6, and ADAMTS9-AS2 are associated with immune-related adverse effects in ICI-treated patients with cancer","volume":"13","author":"Raj","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2025.100375","article-title":"Tape strip profiling of checkpoint inhibitor\u2013associated dermatitis highlights pan-t-cell activation: a pilot study","volume":"5","author":"Powers","year":"2025","journal-title":"JID Innov"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011682","article-title":"Circulating immunoregulatory b cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma","volume":"13","author":"Willsmore","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00262-025-03983-8","article-title":"Single-cell transcriptome sequencing reveals the immune microenvironment in bronchoalveolar lavage fluid of checkpoint inhibitor-related pneumonitis","volume":"74","author":"Zheng","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115221","article-title":"Gut microbiome and immune checkpoint inhibitor toxicity","volume":"216","author":"Verheijden","year":"2025","journal-title":"Eur J Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2026.2618937","article-title":"Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia","volume":"17","author":"Xu","year":"2026","journal-title":"Immunotherapy"},{"key":"B73","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s40001-024-01741-7","article-title":"Univariable and multivariable Mendelian randomization study identified the key role of gut microbiota in immunotherapeutic toxicity","volume":"29","author":"Liu","year":"2024","journal-title":"Eur J Med Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12882-024-03754-0","article-title":"Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer","volume":"25","author":"Liu","year":"2024","journal-title":"BMC Nephrol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"10733","DOI":"10.1038\/s41467-024-54180-7","article-title":"Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105427","article-title":"Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors","volume":"109","author":"Liu","year":"2024","journal-title":"eBioMedicine"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13770","article-title":"Single-cell RNA sequencing reveals the altered innate immunity in immune checkpoint inhibitor-related myocarditis","volume":"172","author":"Lou","year":"2024","journal-title":"Immunology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007305","article-title":"Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223792","article-title":"Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006570","article-title":"Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Caulfield","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1099063","article-title":"Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1144534","article-title":"Dynamic gut microbiota changes in patients with advanced Malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events","volume":"13","author":"Zeng","year":"2023","journal-title":"Front Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2217\/pgs-2022-0113","article-title":"Association between genetic variants and the risk of nivolumab-induced immune-related adverse events","volume":"23","author":"Udagawa","year":"2022","journal-title":"Pharmacogenomics"},{"key":"B85","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1186\/s12885-021-08530-z","article-title":"Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer","volume":"21","author":"Chau","year":"2021","journal-title":"BMC Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763468","article-title":"Intestinal microbiota and gene expression reveal similarity and dissimilarity between immune-mediated colitis and ulcerative colitis","volume":"11","author":"Sakai","year":"2021","journal-title":"Front Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13990","article-title":"Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events","volume":"12","author":"Tan","year":"2021","journal-title":"Thorac Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"337","DOI":"10.12688\/f1000research.22715.1","article-title":"Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry","volume":"9","author":"Diamandis","year":"2020","journal-title":"F1000Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"11645","DOI":"10.1038\/s41467-025-66509-x","article-title":"Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients","volume":"16","author":"Lin","year":"2025","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40959-024-00289-z","article-title":"Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort","volume":"10","author":"Jaber Chehayeb","year":"2024","journal-title":"Cardiooncology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02803-3","article-title":"Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma","volume":"30","author":"Bj\u00f6rk","year":"2024","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1038\/s41467-023-42997-7","article-title":"Gut microbial structural variation associates with immune checkpoint inhibitor response","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma\u2013producing CD8+ tissue resident memory t cells are a targetable hallmark of immune checkpoint inhibitor\u2013colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922867117","article-title":"Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer","volume":"117","author":"Khan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798","article-title":"Early b cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2427234123","article-title":"A pharmacovigilance data-driven approach to reveal high fatal adverse events following checkpoint immunotherapy","volume":"123","author":"Sun","year":"2026","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1945286\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:32Z","timestamp":1790055572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1945286\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2026.1945286"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1945286","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1945286"}}